CH-5137291

CC1(C)N(C(=S)N(C1=O)C2=CC=C(C#N)C(=C2)C(F)(F)F)C3=CC=CC(=N3)S(N)(=O)=O

InChIKey=JIIHFLNYGVNTFP-UHFFFAOYSA-N

InChI=1S/C18H14F3N5O3S2/c1-17(2)15(27)25(11-7-6-10(9-22)12(8-11)18(19,20)21)16(30)26(17)13-4-3-5-14(24-13)31(23,28)29/h3-8H,1-2H3,(H2,23,28,29)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

PubMed

Title	Date	PubMed
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.	2010 Dec 1	21050768
Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.	2011 Sep	21308717

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:03:24 GMT 2023` Edited by `admin` on `Sat Dec 16 08:03:24 GMT 2023`
Record UNII	A5ZX7J376H
Record Status	`Validated (UNII)`
Record Version

Name

Type

Language

CH-5137291

Common Name

English

2-PYRIDINESULFONAMIDE, 6-(3-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXO-1-IMIDAZOLIDINYL)-

Systematic Name

English

Code System Code Type Description

CAS

1043446-39-4

Created by admin on Sat Dec 16 08:03:24 GMT 2023 , Edited by admin on Sat Dec 16 08:03:24 GMT 2023

PRIMARY

PUBCHEM

44462785

Created by admin on Sat Dec 16 08:03:24 GMT 2023 , Edited by admin on Sat Dec 16 08:03:24 GMT 2023

PRIMARY

FDA UNII

A5ZX7J376H

Created by admin on Sat Dec 16 08:03:24 GMT 2023 , Edited by admin on Sat Dec 16 08:03:24 GMT 2023

PRIMARY

Related Record Type Details


					A5ZX7J376H

ACTIVE MOIETY